Portfolio Highlights: Clinical and Financing Updates of QureBio, HAYA and Xlement
Time: 2022-03-02
Source: Viva Biotech
[Abstract]:Over the past 1 month, our portfolio companies have had great progress.

QureBio Announced that Its Phase II Clinical Trial Application of Q-1802 has been accepted by CDE



On January 26th, QureBio, invested and incubated by Viva BioInnovator, announced that its Phase II clinical trial application of Q-1802 for GI tract multi-tumor Indications has been formally accepted by the Center for Drug Evaluation (CDE) of National Medical Products Administration (NMPA). Q-1802 is the first CLDN18.2/PD-L1 dual antibody to reach human trial in the world.


HAYA Closes US$5M Seed Extension Led by Humboldt Fund and Establishes U.S. Location



HAYA Therapeutics, SA, a company developing precision medicines that target tissue and cell-specific long non-coding RNAs (lncRNAs). On February 9th, the company announced that it has successfully closed a US$5 million seed extension led by Humboldt Fund to advance the development of its anti-fibrotic lead program targeting Wisper, a cardiac long non-coding RNA, with participation from existing investors including Viva BioInnovator Broadview Ventures, Apollo Health Ventures, BERNINA BioInvest, 4See Ventures and Schroder Adveq. This brings the total amount raised for the seed round to approximately US$25 million. In addition, HAYA has established a new laboratory space at JLABS @ San Diego, part of Johnson & Johnson Innovation’s global network of life science incubators.


Xlement Closes Multi-Million Dollars A Round to Accelerate Production of NanoSPR Biochips and IVD instruments



On February 18, 2022, Xlement, a devoted NanoSPR biochip and instruments biotech company that previously invested and incubated by Viva BioInnovator, announced the completion of Multi-Million Dollars A Round fundraising. Volcanics Venture and Neovision Capital co-led this round. 

Media contact:
Contact Us